5v4e - Revision history

OCA at 04:50, 21 November 2024

2024-11-21T04:50:44Z

← Older revision		Revision as of 04:50, 21 November 2024
Line 1:		Line 1:

	==Engineered human IgG Fc domain glyco801 (Fc801)==		==Engineered human IgG Fc domain glyco801 (Fc801)==
	<StructureSection load='5v4e' size='340' side='right' caption='[[5v4e]], [[Resolution\|resolution]] 3.22Å' scene=''>		<StructureSection load='5v4e' size='340' side='right'caption='[[5v4e]], [[Resolution\|resolution]] 3.22Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5v4e]] is a 8 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V4E OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5V4E FirstGlance]. <br>		<table><tr><td colspan='2'>[[5v4e]] is a 8 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V4E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5V4E FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>~~</td></tr>~~		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 3.216Å</td></tr>
	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IGHG1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>		<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5v4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v4e OCA], [~~http~~://pdbe.org/5v4e PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5v4e RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5v4e PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5v4e ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5v4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v4e OCA], [https://pdbe.org/5v4e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5v4e RCSB], [https://www.ebi.ac.uk/pdbsum/5v4e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5v4e ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
	[~~[http~~://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[~~http~~://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.		[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[https://omim.org/entry/254500 254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.
			== Function ==
			[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 23:		Line 25:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: ~~Human~~]]		[[Category: Homo sapiens]]
	[[Category: ~~Marshall, N~~]]		[[Category: Large Structures]]
	[[Category: ~~Yan, W~~]]		[[Category: Marshall N]]
	[[Category: ~~Zhang, Y J~~]]		[[Category: Yan W]]
	[[Category: ~~Antibody engineering]]~~		[[Category: Zhang YJ]]
	~~[[Category: Fc fragment]]~~
	~~[[Category: Igg]]~~
	~~[[Category: Immune system~~]]

OCA at 12:54, 6 November 2017

2017-11-06T12:54:08Z

← Older revision		Revision as of 12:54, 6 November 2017
Line 3:		Line 3:
	<StructureSection load='5v4e' size='340' side='right' caption='[[5v4e]], [[Resolution\|resolution]] 3.22Å' scene=''>		<StructureSection load='5v4e' size='340' side='right' caption='[[5v4e]], [[Resolution\|resolution]] 3.22Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5v4e]] is a 8 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V4E OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V4E FirstGlance]. <br>		<table><tr><td colspan='2'>[[5v4e]] is a 8 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V4E OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V4E FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
			<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IGHG1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v4e OCA], [http://pdbe.org/5v4e PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v4e RCSB], [http://www.ebi.ac.uk/pdbsum/5v4e PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v4e ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v4e OCA], [http://pdbe.org/5v4e PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v4e RCSB], [http://www.ebi.ac.uk/pdbsum/5v4e PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v4e ProSAT]</span></td></tr>
	</table>		</table>
Line 22:		Line 23:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
			[[Category: Human]]
	[[Category: Marshall, N]]		[[Category: Marshall, N]]
	[[Category: Yan, W]]		[[Category: Yan, W]]

OCA at 09:01, 3 August 2017

2017-08-03T09:01:21Z

← Older revision		Revision as of 09:01, 3 August 2017
Line 1:		Line 1:
	~~'''Unreleased structure'''~~

	The ~~entry 5v4e~~ is ~~ON HOLD until Paper~~ Publication		==Engineered human IgG Fc domain glyco801 (Fc801)==
			<StructureSection load='5v4e' size='340' side='right' caption='[[5v4e]], [[Resolution\|resolution]] 3.22Å' scene=''>
			== Structural highlights ==
			<table><tr><td colspan='2'>[[5v4e]] is a 8 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V4E OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V4E FirstGlance]. <br>
			</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
			<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v4e OCA], [http://pdbe.org/5v4e PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v4e RCSB], [http://www.ebi.ac.uk/pdbsum/5v4e PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v4e ProSAT]</span></td></tr>
			</table>
			== Disease ==
			[[http://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[http://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.
			<div style="background-color:#fffaf0;">
			== Publication Abstract from PubMed ==
			Engineered crystallizable fragment (Fc) regions of antibody domains, which assume a unique and unprecedented asymmetric structure within the homodimeric Fc polypeptide, enable completely selective binding to the complement component C1q and activation of complement via the classical pathway without any concomitant engagement of the Fcgamma receptor (FcgammaR). We used the engineered Fc domains to demonstrate in vitro and in mouse models that for therapeutic antibodies, complement-dependent cell-mediated cytotoxicity (CDCC) and complement-dependent cell-mediated phagocytosis (CDCP) by immunological effector molecules mediated the clearance of target cells with kinetics and efficacy comparable to those of the FcgammaR-dependent effector functions that are much better studied, while they circumvented certain adverse reactions associated with FcgammaR engagement. Collectively, our data highlight the importance of CDCC and CDCP in monoclonal-antibody function and provide an experimental approach for delineating the effect of complement-dependent effector-cell engagement in various therapeutic settings.

	~~Authors:~~ Yan, W., Marshall, N., Zhang, Y.J.		IgG Fc domains that bind C1q but not effector Fcgamma receptors delineate the importance of complement-mediated effector functions.,Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G Nat Immunol. 2017 Aug;18(8):889-898. doi: 10.1038/ni.3770. Epub 2017 Jun 12. PMID:28604720<ref>PMID:28604720</ref>

	~~Description~~: ~~Engineered human IgG Fc domain glyco801 (Fc801)~~		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	~~[[Category: Unreleased Structures]]~~		</div>
	[[Category: ~~Zhang~~, ~~Y.J~~]]		<div class="pdbe-citations 5v4e" style="background-color:#fffaf0;"></div>
			== References ==
			<references/>
			__TOC__
			</StructureSection>
			[[Category: Marshall, N]]
	[[Category: Yan, W]]		[[Category: Yan, W]]
	[[Category: ~~Marshall~~, N]]		[[Category: Zhang, Y J]]
			[[Category: Antibody engineering]]
			[[Category: Fc fragment]]
			[[Category: Igg]]
			[[Category: Immune system]]

OCA at 11:34, 5 April 2017

2017-04-05T11:34:56Z

← Older revision		Revision as of 11:34, 5 April 2017
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 5v4e is ON HOLD		The entry 5v4e is ON HOLD until Paper Publication

	Authors: ~~Wupeng~~ Yan, ~~Nicholas~~ Marshall, ~~Yan Jessie~~ Zhang		Authors: Yan, W., Marshall, N., Zhang, Y.J.

	Description: Engineered human IgG Fc domain glyco801 (Fc801)		Description: Engineered human IgG Fc domain glyco801 (Fc801)
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	[[Category: ~~Wupeng~~ Yan, ~~Nicholas~~ Marshall, ~~Yan Jessie Zhang~~]]		[[Category: Zhang, Y.J]]
			[[Category: Yan, W]]
			[[Category: Marshall, N]]

OCA: Protected "5v4e" [edit=sysop:move=sysop]

2017-03-15T19:45:19Z

Protected "5v4e" [edit=sysop:move=sysop]

← Older revision	Revision as of 19:45, 15 March 2017
(No difference)

OCA: New page: '''Unreleased structure''' The entry 5v4e is ON HOLD Authors: Wupeng Yan, Nicholas Marshall, Yan Jessie Zhang Description: Engineered human IgG Fc domain glyco801 (Fc801) [[Category: U...

2017-03-15T19:45:17Z

New page: '''Unreleased structure''' The entry 5v4e is ON HOLD Authors: Wupeng Yan, Nicholas Marshall, Yan Jessie Zhang Description: Engineered human IgG Fc domain glyco801 (Fc801) [[Category: U...

New page

'''Unreleased structure'''

The entry 5v4e is ON HOLD

Authors: Wupeng Yan, Nicholas Marshall, Yan Jessie Zhang

Description: Engineered human IgG Fc domain glyco801 (Fc801)
[[Category: Unreleased Structures]]
[[Category: Wupeng Yan, Nicholas Marshall, Yan Jessie Zhang]]